Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855229 · ClinicalTrials.gov registry record
Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains
A clinical trial of Translational Electrophysiology, sponsored by Mclean Hospital.
- Completed
- Registry status
- 222
- Enrollment target
- 1
- Study location
NCT02855229 is a study of Translational Electrophysiology that has completed, run by Mclean Hospital. The registered enrollment target is 222 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02855229, a study of Translational Electrophysiology, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- 222 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this multi-disciplinary research program is to develop and optimize new cross-species translational assessments of reward and cognition that will not only be assessed in parallel in humans and rats, but also produce neurophysiological and behavioral metrics that can be objectively compared across species. The research will build on prior studies by further developing and optimizing (in Phase 1), then validating via pharmacological challenge (in Phase 2), the following assays in both humans and rats: 1. advanced neurophysiological and computational modeling techniques to record and analyze EEG activity within and across species; and 2. behavioral assessments of reward learning, cognitive control, and cognitive flexibility will be analyzed within and across species. The second phase of the study will test the translational validity of these assays, by assessing the impact of a targeted drug on task performance and EEG activity in both species.
Conditions Studied
Interventions
- DRUG Methylphenidate
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2020-08-15 |
| Est. Completion | 2021-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855229
The ClinicalTrials.gov registry entry for NCT02855229 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Translational Electrophysiology appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate is the first listed.
NCT02855229 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02855229 about?
NCT02855229 is a clinical study titled "Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains". The overarching goal of this multi-disciplinary research program is to develop and optimize new cross-species translational assessments of reward and cognition that will not only be assessed in parallel in humans and rats, but also produce neurophysiological and behavioral metrics that can be object...
What is the current status of trial NCT02855229?
This trial is currently completed. The enrollment target is 222 participants. The study started on 2020-08-15. Estimated completion is 2021-08-31.
What conditions does trial NCT02855229 study?
This clinical trial studies the following conditions: Translational Electrophysiology.
What interventions are being tested in trial NCT02855229?
The interventions under investigation include: Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT02855229?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02855229 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.